Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Aerie Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01789736
First received: February 9, 2013
Last updated: February 17, 2014
Last verified: February 2014

February 9, 2013
February 17, 2014
February 2013
June 2013   (final data collection date for primary outcome measure)
Mean diurnal IOP [ Time Frame: 28 Days ] [ Designated as safety issue: No ]
The primary efficacy endpoint will be the mean diurnal IOP across subjects within treatment group and time point at Day 28.
Same as current
Complete list of historical versions of study NCT01789736 on ClinicalTrials.gov Archive Site
IOP [ Time Frame: 7-28 days ] [ Designated as safety issue: No ]
Secondary efficacy endpoints will include: mean IOP across subjects within treatment group at each post-treatment timepoint, mean change from diurnally adjusted baseline IOP at each timepoint, mean percent change from diurnally adjusted baseline IOP at each timepoint, mean diurnal IOP at other visits, and mean change from the baseline mean diurnal IOP at each visits.
Same as current
Not Provided
Not Provided
 
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Study Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components

In the double-masked, randomized, multi-center, active-controlled parallel study, patients will be randomized to receive either a fixed dose combination of AR-12286 and travoprost, AR-12286, or travoprost. The hypothesis is that there is no difference between each treatment arm.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Open Angle Glaucoma
  • Ocular Hypertension
  • Drug: PG286 Ophthalmic Solution 0.5%
    PG286 Ophthalmic Solution
  • Drug: AR-12286 Ophthalmic Solution 0.5%
    AR-12286 Ophthalmic Solution 0.5%
  • Drug: Travoprost Ophthalmic Solution 0.004%
    Travoprost Ophthalmic Solution 0.004%
  • Experimental: PG286
    PG286 Ophthalmic Solution q.d. O.U.
    Intervention: Drug: PG286 Ophthalmic Solution 0.5%
  • Experimental: AR-12286 Ophthalmic Solution 0.5%
    AR-12286 Ophthalmic Solution 0.5% q.d. O.U.
    Intervention: Drug: AR-12286 Ophthalmic Solution 0.5%
  • Active Comparator: Travoprost 0.004%
    Travoprost 0.004% q.d. O.U.
    Intervention: Drug: Travoprost Ophthalmic Solution 0.004%
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
234
June 2013
June 2013   (final data collection date for primary outcome measure)

Subject inclusion criteria

  1. 18 years of age or greater.
  2. Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
  3. Unmedicated (post-washout) IOP ≥ 22 mm Hg at 2 qualification visits (08:00 hr), 2-7 days apart. At second qualification visit, IOP >21 mmHg at 10:00 and 16:00 hrs.
  4. Corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200).
  5. Able and willing to give signed informed consent and follow study instructions.

Subject exclusion criteria

Excluded from the study will be individuals with the following characteristics:

Ophthalmic (in either eye):

  1. Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles. Note: Previous laser peripheral iridotomy is NOT acceptable.
  2. Intraocular pressure > 35 mm Hg, or use of more than two ocular hypotensive medications within 30 days of screening. Note: fixed dose combinations count as two medications.
  3. Known hypersensitivity to any component of the formulation (benzalkonium chloride, zinc, etc.), travoprost, or to topical anesthetics.
  4. Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s).
  5. Refractive surgery in study eye(s) (e.g., radial keratotomy, PRK, LASIK, etc.).
  6. Ocular trauma within the six months prior to screening, or ocular surgery or laser treatment within the three months prior to screening.
  7. Evidence of ocular infection, inflammation, clinically significant blepharitis, conjunctivitis, or a history of herpes simplex keratitis at screening.
  8. Ocular medication of any kind within 30 days of screening, with the exception of a) ocular hypotensive medications (which must be washed out according to the provided schedule), b) lid scrubs (which may be used prior to, but not after screening) or c) lubricating drops for dry eye (which may be used throughout the study).
  9. Clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe (e.g., cup-disc ratio > 0.8).
  10. Central corneal thickness greater than 600 µm.
  11. Any abnormality preventing reliable applanation tonometry of either eye.

    Systemic:

  12. Clinically significant abnormalities (as determined by the investigator) in laboratory tests at screening.
  13. Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.
  14. Participation in any investigational study within 30 days prior to screening.
  15. Changes of systemic medication within 30 days prior to screening, or anticipated during the study, that could have a substantial effect on IOP.
  16. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01789736
PG286-CS202
No
Aerie Pharmaceuticals
Aerie Pharmaceuticals
Not Provided
Not Provided
Aerie Pharmaceuticals
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP